Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant tislelizumab plus TP chemotherapy with reduced-margin surgery for locally advanced tongue squamous cell carcinoma
ChiCTR2400080185Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, cisplatin, paclitaxel and docetaxel in squamous cell carcinoma of the tongue (TSCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 2-year disease-free survival rate. Started Jan 2024; status: recruiting.
02
Drugs
tislelizumabcisplatinpaclitaxeldocetaxel
03
Conditions
squamous cell carcinoma of the tongue (TSCC)
Beyond the preview
Go deeper on ChiCTR2400080185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080185.